Table of contents


Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2020 on request of the sponsor.

On 22 February 2018, orphan designation (EU/3/18/1981) was granted by the European Commission to Midatech Pharma Plc, United Kingdom, for mertansine functionalised gold nanoconjugate for the treatment of hepatocellular carcinoma.

The sponsorship was transferred to Midatech Pharma Espana Sociedad Limitada in November 2019.

Key facts

Active substance
Mertansine functionalised gold nanoconjugate
Disease / condition
Treatment of hepatocellular carcinoma
Date of first decision
EU designation number

Sponsor's contact details

Midatech Pharma Espana Sociedad Limitada 
Parque Tecnologico Empresarial Zamudio 
Edif 800 2 Planta 
48160 Derio Bizkaia 
Tel. +34 944034020

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating